New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
15:23 EDTFOSL, URS, TTWO, HTHT, RVNCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Fossil Group (FOSL), consensus $1.17; URS Corporation (URS), consensus 68c; Take-Two (TTWO), consensus 10c; China Lodging (HTHT), consensus (31c); Revance Therapeutics (RVNC), consensus (87c).
News For FOSL;URS;TTWO;HTHT;RVNC From The Last 14 Days
Check below for free stories on FOSL;URS;TTWO;HTHT;RVNC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
06:01 EDTTTWOJuly NPD video game software sales fell 15%, says Piper Jaffray
Subscribe for More Information
August 14, 2014
10:05 EDTURSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Adidas (ADDYY) downgraded to Neutral from Buy at Goldman... Fabrinet (FN) downgraded at B. Riley... Freeport McMoRan (FCX) downgraded at Stifel... Infosys (INFY) downgraded to Hold from Buy at Jefferies... InterMune (ITMN) downgraded to Neutral from Buy at Goldman... Jones Energy (JONE) downgraded to Neutral from Overweight at JPMorgan... LVMH Moet Hennessy (LVMUY) downgraded to Neutral from Buy at Goldman... Madison Square Garden (MSG) downgraded to Hold from Buy at Topeka... Qualys (QLYS) downgraded to Sector Perform from Outperform at RBC Capital... SeaWorld (SEAS) downgraded to Market Perform from Outperform at Wells Fargo... Theravance Biopharma (TBPH) downgraded to Underperform from Neutral at RW Baird... URS Corporation (URS) downgraded to Neutral from Buy at Sterne Agee... ViaSat (VSAT) downgraded to Perform from Outperform at Oppenheimer... Wynn Resorts (WYNN) downgraded to Hold from Buy at Gabelli.
06:33 EDTURSURS Corporation downgraded to Neutral from Buy at Sterne Agee
Subscribe for More Information
August 12, 2014
19:02 EDTFOSLOn The Fly: After Hours Movers
Subscribe for More Information
16:18 EDTURSURS Corporation reports Q2 EPS with items $1.27, consensus 74c
Subscribe for More Information
16:09 EDTFOSLFossil extends licensing agreement with Giorgio Armani through 2023
Fossil Group announced that it has extended a global watch licensing agreement with Giorgio Armani S.p.A through 2023. The Armani Group first partnered with Fossil Group in 1997 to design, develop and distribute watches under the Emporio Armani label. Over the history of the relationship, jewelry was added in 2002, watches under the Armani Exchange brand in 2008 and a Swiss made collection of timepieces under the Emporio Armani Swiss Made label launched in 2014.
16:08 EDTFOSLFossil sees FY14 EPS $6.95-$7.35, consensus $7.13
Subscribe for More Information
16:08 EDTFOSLFossil sees Q3 EPS $1.77-$1.84, consensus $1.84
Subscribe for More Information
16:07 EDTFOSLFossil reports Q2 EPS 98c, consensus 96c
Subscribe for More Information
15:23 EDTFOSL, URSNotable companies reporting after market close
Subscribe for More Information
14:35 EDTFOSLFossil August 103 straddle priced for 8.4% move into Q2
Subscribe for More Information
14:28 EDTFOSLFossil technical notes before earnings
In the prior three months the shares have underperformed the broader averages with a loss of over 8%. The downtrend in the shares on a longer-term basis has been underway since shares hit a peak of price in early November 2013. That downtrend has been characterized by volatile bursts higher in price away from the broader downtrend that fail to hold. On disappointing news, a breakdown below $100 would seem highly probable. For the prior two years the $100 area has been both resistance and then support. A break below $100 would be therefore more technically significant. Support below on an increasing band of disappointment would be at $97.96, $92.80, and $89.33. If the news is more positive than expected, a move up to the recent pivot at $108.08 would be the first major resistance encountered. A breakout above $110 would turn the shares from bearish to neutral with additional resistance then at $114.12. The short-base is large at over 8% of the float short which could add to a potential short-squeeze on stronger than expected news.
07:40 EDTHTHTChina Lodging Group price target raised to $29 from $27 at Brean Capital
Subscribe for More Information
August 11, 2014
17:09 EDTHTHTChina Lodging Group sees Q3 net revenue growth 20%-22%, consensus $1.39B
"Thanks to the strong growth in China travel market and our proven results, we have continued to see a robustly growing pipeline, with another record high of 505 hotels as end of second quarter this year. Our midscale hotels saw a remarkable progress with 137 hotels in operation and 83 hotels in the pipeline. The same-hotel RevPAR for midscale hotels registered low teen year-over-year increase in the first half. We remain confident in the growth of China economy hotel market as only 20% of the market has been consolidated so far. Our economy hotel brands, HanTing Hotel and Hi Inn, both are well on track to expand across the country. In addition, we recently launched Elan Hotel, which is a new non-standardized economy hotel brand. We expect to further capture the opportunity for consolidation in the economy hotel market with the brand portfolio in the coming years," commented Mr. Qi Ji, founder, Executive Chairman and CEO of China Lodging Group.
17:08 EDTHTHTChina Lodging reports Q2 adj EPS 34c, may not compare to consensus $1.76
Subscribe for More Information
August 8, 2014
06:42 EDTRVNCRevance risk not heightened from FDA guidance, says Piper Jaffray
Piper Jaffray does not see heightened risk around Revance's RT001 after the FDA issued draft guidance on clinical endpoints for botulinum toxin products for the treatment of upper facial lines. The firm reiterates an Overweight rating on the stock with a $44 price target.
August 7, 2014
13:55 EDTRVNCRevance slides further following FDA's facial line product guidance
Subscribe for More Information
13:28 EDTRVNCRevance Therapeutics pullback a buying opportunity, says Cowen
Cowen says that while the FDA draft guidance on upper facial lines was surprising, it believes Revance's protocol for RT001 will be found acceptable. The firm recommends adding to Revance positions following the recent pullback and keeps an Outperform rating on the stock with a $55 price target.
11:20 EDTFOSLFossil August volatility elevated into Q2 and outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use